Saskatchewan, a western Canadian province of one million, has a large rural and aging population. In 2011, 39.1% of the Saskatchewan population lived in rural areas and small towns. 4 People aged 46-64 years in 2011 made up more than one quarter of the Saskatchewan population. One in five residents living in a rural area or small town is 65 years or older. 5 to address and alleviate the gaps in delivery of prompt dementia care to the aging population in rural Saskatchewan, we developed the Rural and Remote Memory Clinic (RRMC) in 2004. the separation of health care professionals and patients by distance is addressed through the use of telehealth videoconferencing. Follow-up appointments are delivered through telehealth to minimize the time, expense, and inconvenience of travel for patients and their caregivers. the Memory Clinic's goals are to provide an interdisciplinary assessment of dementia, reduce repeated patient travel to various health care professionals, and shorten time to diagnosis. It has proven to be a successful model in providing integrated, efficient, and tailored patient care. More information on the Rural and Remote Memory Clinic is available elsewhere. [6] [7] [8] [9] Studies examining predictors of cholinesterase inhibitor discontinuation have suggested that female gender, more severe cognitive impairment, and absence of social assistance predict a higher likelihood of discontinuation. Conversely, frequent physician visits, higher Chronic Disease scores and greater functional impairment predicted a lower likelihood of discontinuation. 3 A Japanese study suggested that patients with more severe cognitive impairment (CDR=3) discontinued therapy earlier than those with less severe impairment, with the most common reason being ineffectiveness of the medication. 10 Although some studies have been done to identify predictors and rates for the discontinuation of cholinesterase inhibitor therapy, more research is needed in this area. Furthermore, predictors may vary in different populations and settings. thus, it is important to identify and compare them. the results of this research may help plan the treatment of patients with dementia. It may also benefit their caregivers and the health care systems that support these patients.
METHODS

Data Collection and Ethical Consideration
Data Collection began in March 2004 at the Rural and Remote Memory Clinic (RRMC) in Saskatoon, Saskatchewan. Family physicians referred their non-institutionalized patients to the clinic. the University of Saskatchewan behavioural Research ethics board granted ethical approval for this study. Prior to participation, all patients and their families gave informed consent. Due to the RRMC being directed toward patients with early stage memory loss, we assumed that most patients were competent to provide informed consent, although complete patient assessment must be conducted to confirm this assumption. therefore, a family member was asked to witness the consent protocol for the patient, and the patient was aware that a family member co-signed the consent forms. the assessment began with a pre-clinic telehealth appointment followed by an in-person clinic visit several weeks later. During this visit, the patient and family members met with and were jointly interviewed by a neurologist, neuropsychology team, and physical therapist, following which clinic team members assessed the patient individually. A standardized neuropsychological battery was administered. 6 Family members completed a questionnaire that included measures of caregiver burden, distress, and health, and ratings of the patient's behaviors and functional ability. Patients also completed a questionnaire that included self-ratings of mood, memory, functional ability, and quality of life. Unless recent imaging had been done, all patients underwent computed tomography (Ct) brain scans. Following an end-of-day team conference, the neurologist and neuropsychology team met with the patient and family members to discuss the diagnosis and make treatment recommendations. At this time, detailed education and counseling was given to patients and caregivers by the Memory Clinic team regarding action and expected effect of cholinesterase inhibitor therapy, as well as techniques to avoid side effects such as taking medication with food. Patients and caregivers were provided with ample time for questions and clarifications of the disease and treatment. Patients were seen in follow-up, either in person or over telehealth, at six weeks, 12 weeks, six months and annually thereafter. Additional appointments were scheduled as needed. At the six-month follow-up appointment, it was noted whether or not the patient was still on cholinesterase inhibitor therapy.
Participants
We included in the present study the first 318 individuals living in rural and remote areas in Saskatchewan who were referred to the RRMC. the participants included in this study were the 63 patients started on a cholinesterase inhibitor at clinic day and who attended a six-month follow up appointment. those already taking a cholinesterase inhibitor at presentation as well as those who did not attend the six-month follow up appointment were not included in the present study.
Measures
Patient and caregiver questionnaires administered at the clinic day appointment provided the socio-demographic, clinical, and functional independent variables. Sociodemographic variables were age, sex, marital status, years of formal education, ethnicity, and number of other chronic diseases (table 1). Clinical variables were smoking status, times per week of exercise and alcoholic drinks per week. Caregiverrated functional status of the patient was assessed using various scales outlined below:
1. Functional Assessment Questionnaire (FAQ): the FAQ is a 10-item screening tool assessing independence in daily activities and universal skills among older adults. 11 the items are rated on a 4-point scale ranging from 0 (independence) to 3 (dependence). Overall scores range from 0-30, with a higher score signifying greater patient dependency.
Neuropsychiatric Inventory Severity Scale (NPI-S):
the NPI measures behavioural changes in patients with dementia. 12 the NPI-S, one component of the NPI scale, was used for this study. this NPI-S is a 12-item scale in which each item is rated from 1 (mild) to 3 (severe). Overall scores range from 1-36, with a higher score signifying more severe psychiatric symptoms.
The Bristol Activities of Daily Living Scale (BADL):
the bADl is an instrument containing 20 daily living abilities in four areas: mobility, instrumental activities of daily living, self-care, and orientation. 13 the items are rated on a scale from 0 (independence) to 3 (dependence). Overall scores range from 0-60, with a higher score signifying greater dependence.
Quality of Life of the Patient (caregiver rated) (QOLCG):
the QOlCG uses a 13-item scale that rates various aspects of the patient's life. 14 the items are rated on a scale from 1 (poor) to 4 (excellent). Overall scores range from 13-52, with a lower score signifying poorer quality of life of the patient.
Self-rated functional and lifestyle status of the patient was assessed using various scales outlined below:
Quality of life of the Patient (patient rated) (QOLPT): the
QOlPt uses a 13-item scale that rates various aspects of the patient's life. 14 the items are rated on a scale from 1 (poor) to 4 (excellent). Overall scores range from 14-56, with a lower score signifying poorer quality of life of the patient.
Center for Epidemiologic Studies-Depression Scale (CES-D):
the CeS-D is a 20-item scale that assesses depressive symptoms. 15 the items are rated on a scale from 0 (rarely of none of the time) to 3 (most or all of the time). Overall scores range from 0-60, with a higher score signifying more depressive symptoms.
Life Concerns Scale (LC): the lC scale, a scale
developed for the purpose of this study, assesses the patient's stress and concern with various aspects of his/her life. the 14 items are rated on a scale from 0 (no concern) to 4 (extreme concern), with a higher score signifying greater patient stress. 4. Instrumental Activities of Daily Living (IADL): the IADl is a 9-item scale that measures the ability of the patient to perform daily tasks. 16 the items are rated on a scale from 1 (being unable to perform the task independently) to 3 (being able to perform the task independently). Overall scores range from 9-27, with a higher score signifying greater level of function. 5. Self-rating of Memory (MEM): the MeM is a 15-item scale that assesses memory of the patient. 17 each item is rated from -2 (much worse) to +2 (much better). Overall scores range from -30 to +30, with a lower or more negative score signifying worse memory symptoms.
Although multiple neuropsychological tests were administered, for the purposes of this study global cognitive impairment was assessed with the Mini-Mental State exam (MMSe), as this test is required for coverage by the Saskatchewan Drug Plan.
Outcome: Discontinuation by six months
the dependent variable in this study was discontinuation of cholinesterase inhibitor therapy by six months. Switching from one cholinesterase inhibitor to another was not considered discontinuation.
Statistical Analysis
Data were analyzed using IbM SPSS version 19.0 software. Descriptive analysis was performed for all of the variables in order to characterize the sample. Categorical variables were described in terms of frequency and percentage. Continuous variables were described in terms of mean and standard deviation.
A univariate logistic regression analysis was carried out in order to examine the association between each potential independent variable and the binary outcome variable of discontinuation by six months. based on bi-variable analysis, independent variables associated with the dependent variable with a p<0.20 became candidates for a multivariable logistic regression model. All variables that were significantly correlated with discontinuation of cholinesterase inhibitor therapy (p<0.05), as well as important individual factors (age and sex) were retained in the final multivariable model. the goodness of fit statistic for the final model was identified using the Hosmer and lemeshow test. the strength of associations was presented by odds ratios and their 95% confidence intervals.
RESULTS
Study Population
the total number of patients seen was 318. For many patients, a cholinesterase inhibitor was not considered due to 
Bivariate and multivariate analyses
All independent variables underwent bivariate analysis with discontinuation of cholinesterase inhibitor therapy by or at six months as the dependent variable. Age, sex, marital status, ethnicity, smoking status, times per week of exercise, alcoholic drinks per week, MMSe clinic day scores and the presence of other health conditions were not significantly associated with discontinuation. the functional and lifestyle assessment scales (FAQ, IADl, bADl, QOlPt, QOlCG, lC, MeM, CeS-D, and NPIS) were also not significantly associated with discontinuation in the bivariate analysis (table 2). the mean difference in MMSe clinic day scores between patients who discontinued therapy by six months and those who continued was examined, but MMSe clinic day scores were not significantly different between the two groups of patients (p=0.27) ( table 3) .
Years of formal education, which differed significantly between patients who continued or discontinued treatment, was selected from the bivariate analysis and used in the multivariate logistic regression analysis, where it remained significant (p<0.05). the greater the years of formal education, the lower the rate of discontinuation of therapy by six months. Age and sex, important individual factors and cited in the literature as significant, were also included in the multivariate logistic regression analysis. by including age and sex, we made sure that any effects of these variables were captured in the model (table  4) . the final selected model satisfied the goodness of test criteria (Chi Squared Statistics χ 2 =10.43, degrees of freedom=8, P value=0.24).
DISCUSSION
the objective of this study was to obtain sociodemographic/economic, clinical, and functional predictors of cholinesterase inhibitor therapy discontinuation by six months. Knowing possible predictors for cholinesterase inhibitor discontinuation is valuable to clinicians, their patients, and to the health care system. A limitation of this study may be small sample size. Few studies have examined predictors of cholinesterase discontinuation beyond age, sex, and the type of cholinesterase inhibitor. 3 between donepezil, galantamine, and rivastigmine 18, 19 , between galantamine and rivastigmine 20 , and between two different doses of donepezil. 21 Further studies have looked at switching between cholinesterase inhibitors 22 and creating guidelines for cholinesterase inhibitor discontinuation. 23 the strengths of the current study include the sample, which consisted of noninstitutionalized patients with heterogeneous ethnic backgrounds allowing for generalization to a larger population, and the extensive patient and caregiver variable data available on these patients.
Of the 63 patients started on a cholinesterase inhibitor, 19 had discontinued cholinesterase inhibitor therapy by six months. Our discontinuation rate of 30.2% (persistence/continuation rate of 69.8%) was consistent with the results of a retrospective cohort study from the Netherlands, which found that at six months, the cholinesterase inhibitor discontinuation rate was 30.8%. 20 Another study found that over 40 months, 84% of patients discontinued therapy with the one-year risk of discontinuation being 66.4%. 3 In a study from Quebec, persistence of cholinesterase inhibitor therapy at one year was found to be 45.3%. 24 Using logistic regression analysis, we identified years of formal education as the only significant predictor of drug discontinuation. We found an inverse correlation between years of formal education and discontinuation by six months. Previous research has suggested that education plays a significant role in Alzheimer's disease and other dementias, pertaining to risk and progression of disease. It is interesting that we have found education to also be a predictor for dementia therapy persistence. We speculate that those with more years of formal education may better understand and appreciate the importance of continuing therapy. Negative side effects, which may be considered minor in comparison to the effects of the illness, may be dealt with more patiently for this reason, resulting in higher continuation rates among those with higher education.
None of the demographic variables or patient variables (FAQ, IADl, bADl, QOlPt, QOlCG, lC, MeM, CeS-D, NPIS), predicted discontinuation of cholinesterase inhibitor therapy. thus, in this study, ability to perform activities of daily living, patient quality of life, self-rated memory, mood, and behavioral symptoms did not have a major impact on discontinuation of anti-dementia drug treatment. earlier studies have reported female gender, lower MMSe scores (higher level of cognitive impairment), and lack of social assistance as predictors of discontinuation. 3 We did not include income or social assistance in our study because the Saskatchewan Drug Plan covers the cost of cholinesterase inhibitor therapy, and almost all patients are covered. New patients are eligible for coverage if, during the three-month trial period, they exhibit an improvement from their initial MMSe by at least 2 points or their FAQ score by -1 point. the MMSe score must also remain above 10 to continue eligibility for drug coverage. 25 Patients who lose eligibility due to ineffectiveness would be likely to discontinue anyway, or if they are advised to continue, begin purchasing it themselves.
A retrospective cohort study using administrative health data from Saskatchewan found that higher chronic disease scores, FAQ scores of 9+ (indicating greater patient dependency), and frequent physician visits decreased the risk of discontinuation 3 , but these factors were not important predictors in the current study, which had a smaller sample size but was able to examine a larger number of patient characteristics.
Our data shows that having more years of formal education decreases the risk of treatment discontinuation in dementia. this could be due to better understanding of treatment goals and higher compliance. Since patients with fewer years of formal education are at an increased risk of discontinuation, more time should be allotted for counseling about the possible positive and negative effects of treatment. Awareness about the effects of the illness in comparison to negative side effects of treatment should be raised with patients.
this study introduces areas for future research. the impact of education on treatment discontinuation needs to be examined further. 
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